Core Insights - Milestone Scientific Inc. is transitioning from a restructuring phase to a growth phase, with expectations for double-digit revenue growth in 2026 and a significant increase in CompuFlo sales [2][3]. Business Update - The company has implemented financial discipline since August 2025, focusing on revenue-generating initiatives and eliminating inefficient spending [2]. - A dental ambassador program was launched in December 2025, and CompuFlo commercialization efforts are being relaunched [2]. - The company is processing registrations for its STA product in Japan, India, and Mexico, while also securing new distribution partners for CompuFlo [2]. Financial Performance - For Q4 2025, total revenue was $2.1 million, a 2.2% increase from $2.0 million in Q4 2024 [4]. - The operating loss for Q4 2025 improved by 89% to $1.1 million compared to $2.0 million in the prior year [5]. - For the full year 2025, total revenue was $9.0 million, a 4% increase from $8.6 million in 2024, driven by higher international dental sales [6][7]. Future Outlook - For 2026, total revenue is expected to be between $9.8 million and $10.2 million, with CompuFlo revenue projected to increase by approximately 400% to between $500,000 and $600,000 [9]. - The company aims to achieve cash flow breakeven by early 2027, focusing on long-term shareholder value [3].

Core Insights - Milestone Scientific Inc. has announced the integration of its CompuFlo® Epidural System at InfiniSurg, LLC, a New Jersey-based ambulatory surgery center, enhancing its clinical practice with advanced technology [1][3][4] Company Overview - Milestone Scientific Inc. (NYSE: MLSS) specializes in developing computerized drug delivery instruments aimed at providing painless and precise injections, focusing on improving patient comfort and safety [5] - The company’s proprietary Dynamic Pressure Sensing Technology® is designed to enhance the precision of injections and reduce complications associated with traditional methods [5] Technology and Innovation - The CompuFlo® Epidural System utilizes objective pressure sensing technology to provide real-time feedback, which may enhance procedural confidence and reduce complications during epidural placements [3][4] - The system aims to establish a new standard of care for epidural procedures by improving procedural efficiency and patient safety through visual and audible feedback mechanisms [4] Leadership and Expertise - Dr. Roman Kosiborod, a highly experienced anesthesiologist and pain management physician, will utilize the CompuFlo® Epidural System at InfiniSurg, bringing over two decades of expertise in interventional pain management [2][3] - InfiniSurg is recognized for its patient-centric approach and commitment to innovation in outpatient surgical care, aligning with Milestone's mission to leverage advanced technologies for better patient outcomes [3]